Navigation Links
BellBrook Labs Develops a TR-FRET Based Transcreener GTPase Assay
Date:7/16/2014

(PRWEB) July 16, 2014

BellBrook Labs announced the launch of a new Transcreener GDP Assay with a TR-FRET (time resolved Forster resonance energy transfer) readout, for sensitive detection of hundreds of enzymes of potential therapeutic interest including the large GTPase family as well as glycosyltransferase enzymes that use GDP-activated sugars; e.g., fucosyltransferases. These and related enzymes are being targeted for a diverse range of diseases, including cancers and anti-microbials, and robust high throughput assays are critical for these efforts. The TR-FRET detection mode is a highly preferred readout for HTS because it relies on a time-gated luminescence signal, making it resistant to prompt fluorescence screening compounds. Like the other Transcreener assays for ADP, AMP/GMP and UDP, the Transcreener GDP assay relies on direct immunodetection of the nucleotide product, and does not depend on coupling enzymes, which are prone to interference from screening compounds. It is the only HTS-compatible GTPase assay that uses direct GDP detection.

GTPases are a large family of enzymes that play diverse roles in normal and disease-related cell processes. It includes small GTPases in the Ras superfamily as well as the Galpha proteins that relay signals from G-protein coupled receptors. Though many GTPases are known to be intimately involved in disease pathways, they have yet to be exploited therapeutically, partially because they are difficult to incorporate into the high throughput screening assays used to identify lead drug molecules. The Transcreener GDP assay overcomes a longstanding problem in GTPase assays because it relies on direct detection of GDP rather than phosphate. Phosphate is a component of many biomolecules and commonly used reagents, and its ubiquitous presence in biological samples causes high background and false positives in the current GTPase enzyme assays. BellBrook’s assay detects GDP - a much more specific product of GTPase enzymes - eliminating the background problems associated with phosphate detection.

The new Transcreener GDP TR-FRET Assay produces a far-red, time-resolved Forester-resonance-energy-transfer (TR-FRET) signal that is less sensitive to interference from fluorescent compounds in comparison to other detection modes. Designed specifically for HTS and featuring a single addition mix-and-read format and room temperature reagent stability, the Transcreener GDP TR-FRET Assay is compatible with plate readers typically found in research labs as well as those used in HTS core facilities.

About BellBrook Labs. BellBrook Labs, LLC develops detection reagents and microfluidic devices that accelerate the discovery of more effective therapies for cancer and other debilitating diseases. Transcreener® is a universal, high throughput biochemical assay platform based on detection of nucleotides, including ADP, GDP, AMP, GMP and UDP which are formed by thousands of cellular enzymes, many of which catalyze the covalent regulatory reactions that are central to cell signaling and represent new opportunities for therapeutic intervention. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12017260.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. BellBrook Labs Seeking Partners to Accelerate Commercialization of Innovative HTS Assay Technologies
2. BellBrook Labs Launches New Turn Key Methyltransferase Assay Kit for Oncogenic Histone Methyltransferase EZH2
3. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
4. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
5. BellBrook Labs Launches Four New Turn-Key Methyltransferase Assay Kits
6. BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
7. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
8. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
9. Kitware Develops Transformative Open-Source Digital Pathology System
10. Atlantic Shores Retirement Community Develops Cutting-Edge Program for CCRC Patient Care
11. Signal-Health Develops Easy Checklist to Identify Possible Sweating Issues in Horses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... McLean, VA (PRWEB) , ... December 07, 2016 ... ... peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced ... Further refinement in defining the optimal patient population and timing of blood sampling ...
Breaking Biology Technology:
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
Breaking Biology News(10 mins):